Epidermal growth factor receptor tyrosine kinase inhibitors for non-small cell lung cancer

doi:10.5306/wjco.v5.i4.646

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 5, Issue 4

This Article

Academic Content and Language Evaluation of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (9271)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-3) series, Tables (1-7) series.

Item

Count

PDF

478

WORD

450

HTML

5680

Figures (1-3)

695

Tables (1-7)

223

Sum=7526

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

922

Download

823

Sum=1745

Oct 10, 2014 (publication date) through Nov 25, 2024

Times Cited of This Article

Times Cited (14)

Journal Information of This Article

Publication Name

World Journal of Clinical Oncology

ISSN

2218-4333

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Topic Highlight

World J Clin Oncol. Oct 10, 2014; 5(4): 646-659
Published online Oct 10, 2014. doi: 10.5306/wjco.v5.i4.646

Table 7 Ongoing trials for advanced activating epidermal growth factor receptor -mutated non-small cell lung cancer

Line	Trial	Phase	Treatment	Primary endpoint
First	LUX-Lung 7 (NCT01466660)	IIb	Afatinib vs Gefitinib	PFS/OS
	ARCHER-1050 (NCT01774721)	III	Dacomitinib vs Gefitinib	PFS
	Tamiya et al[65] (UMIN000005503)	II	CBDCA + TS-1 + gefitinib	PFS
	NEJ 009 (UMIN000006340)	III	CBDCA + PEM + gefitinib vs Gefitinib	OS
Second/third	WJOG (UMIN000002014)	III	Gefitinib vs Erlotinib	PFS
	IMPRESS (NCT01544179)	III	Continuation of gefitinib + CDDP + PEM vs CDDP+PEM	PFS
	JMTO12-01 (UMIN000007765)	II	Continuation of gefitinib + DOC/PEM vs DOC/PEM	PFS

EGFR: Epidermal growth factor receptor; NSCLC: Non-small cell lung cancer; PFS: Progression-free survival; OS: Overall survival; CBDCA: Carboplatin; PEM: Pemetrexed; CDDP: Cisplatin; DOC: Docetaxel.

Citation: Asami K, Atagi S. Epidermal growth factor receptor tyrosine kinase inhibitors for non-small cell lung cancer. World J Clin Oncol 2014; 5(4): 646-659
URL: https://www.wjgnet.com/2218-4333/full/v5/i4/646.htm
DOI: https://dx.doi.org/10.5306/wjco.v5.i4.646